Universities and research institutions are under pressure to design studies that are both rigorous and practical. Traditional methods of measuring mitochondrial function (such as muscle biopsies and complex respirometry) are often invasive, expensive, and difficult to scale. mescreen™ provides a high-throughput platform that uses a simple blood-based assay to assess mitochondrial efficiency, making it easier to incorporate mitochondrial metrics into human studies.

This opens up new possibilities in lifestyle medicine, exercise science, neurodegeneration, cardiometabolic health, and ageing research. Because mescreen™ can be used in wide populations and repeated over time, it supports longitudinal designs, intervention trials, and real-world cohorts where feasibility is critical. The assay is backed by a strong scientific and IP framework, developed in collaboration with world-class mitochondrial researchers.

Data outputs can be integrated with broader datasets – clinical variables, digital biomarkers, questionnaires – and used in advanced analytics such as machine learning and predictive modelling. This makes mescreen™ particularly valuable for groups investigating complex, multi-factorial conditions and healthspan outcomes.

From a partnership perspective, universities can both utilise mescreen™ as a tool and collaborate scientifically with Verséa Discovery’s team on joint projects, publications, and grant applications. This allows academic partners to be early adopters and co-creators in an emerging field of mitochondrial-centric precision health.